Section Arrow
MRNA.NASDAQ
- Moderna
Quotes are at least 15-min delayed:2025/08/31 17:29 EDT
Regular Hours
Last
 24.09
-0.38 (-1.55%)
Day High 
24.38 
Prev. Close
24.47 
1-M High
33.7 
Volume 
8.29M 
Bid
24.11
Ask
24.14
Day Low
23.84 
Open
24.25 
1-M Low
24.13 
Market Cap 
9.52B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 26.39 
20-SMA 26.54 
50-SMA 29.02 
52-W High 79.9587 
52-W Low 23.15 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-7.51/-7.10
Enterprise Value
10.23B
Balance Sheet
Book Value Per Share
24.16
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
3.20B
Operating Revenue Per Share
23.36
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
CARMCarisma Therapeutics0.215-0.013-5.70%-- 
TNFATNF Pharmaceuticals Inc.0.0483-0.0133-21.59%-- 
ADAPAdaptimmune Therapeutics plc0.0589-0.01-14.51%-- 
SRPTSarepta Therapeutics18.2-0.14-0.76%15.76PE
OTLKOutlook Therapeutics0.8512-0.2388-21.91%0.58PE
Quotes are at least 15-min delayed:2025/08/31 17:29 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.